- $1.91bn
- $1.49bn
- $255.87m
Brief: Schrödinger Receives $111.3 Million Distribution From Sale Of Nimbus’S Tyk2 Inhibitor To Takeda
Structure Therapeutics surges 80% in debut after IPO upsize
Brief: Schrödinger Provides Update On Progress Across The Business
Schrodinger Inc reports results for the quarter ended in September - Earnings Summary
Schrodinger Inc expected to post a loss of 65 cents a share - Earnings Preview
Brief: Schrödinger Appoints Geoffrey Porges As Chief Financial Officer
Brief: Schrodinger Inc - QTRLY Loss Per Share $0.67
Brief: Schrödinger Announces FDA Clearance Of Investigational New Drug Application For Sgr-1505, A Malt1 Inhibitor
Schrodinger Inc reports results for the quarter ended in March - Earnings Summary
Brief: Schrödinger Reports First Quarter 2022 Financial Results
Schrodinger Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Schrödinger Reports New Preclinical Data Supporting Advancement Of Its Wee1 Inhibitor Program
Schrodinger Inc reports results for the quarter ended in December - Earnings Summary
Brief: Schrödinger Reports Results For Q4 And Full Year 2021
Schrodinger Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Schrödinger Announces Acquisition Of Xtal Biostructures
Brief: Schrödinger Announces Retirement Of Chief Financial Officer Joel Lebowitz
Data hunters will be Big Pharma’s next prey
Brief: Schrödinger Awarded Grant To Accelerate Drug Discovery In Women’S Health